Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of dama...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Rona M, Jones, Rachel B, Specks, Ulrich, Bond, Simon, Nodale, Marianna, Al-jayyousi, Reem, Andrews, Jacqueline, Bruchfeld, Annette, Camilleri, Brian, Carette, Simon, Cheung, Chee Kay, Derebail, Vimal, Doulton, Tim, Ferraro, Alastair, Forbess, Lindsy, Fujimoto, Shouichi, Furuta, Shunsuke, Gewurz-Singer, Ora, Harper, Lorraine, Ito-Ihara, Toshiko, Khalidi, Nader, Klocke, Rainer, Koening, Curry, Komagata, Yoshinori, Langford, Carol, Lanyon, Peter, Luqmani, Raashid, McAlear, Carol, Moreland, Larry W, Mynard, Kim, Nachman, Patrick, Pagnoux, Christian, Peh, Chen Au, Pusey, Charles, Ranganathan, Dwarakanathan, Rhee, Rennie L, Spiera, Robert, Sreih, Antoine G, Tesar, Vladamir, Walters, Giles, Wroe, Caroline, Jayne, David, Merkel, Peter A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Vasculitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313987/
https://www.ncbi.nlm.nih.gov/pubmed/36958796
http://dx.doi.org/10.1136/ard-2022-223559

Ejemplares similares

Ejemplares similares